Biomaterial Database

Treatment of Schistosoma mansoni infection with oxamniquine in Riyadh, Saudi Arabia. 1985

A K Al-Aska

Single dose therapy with oral oxamniquine was given to 107 Saudi patients suffering from schistosomiasis due to Schistosoma mansoni and they were followed for a period of six months. Clinical cure judged by symptomatic improvement and negative stool counts for S. mansoni eggs was achieved in 88.8%. Side effects were minimal and reversible and it is concluded that this form of treatment is successful for the control of S. mansoni infection.

UI	MeSH Term	Description	Entries
D009600	Nitroquinolines	Quinolines substituted in any position by one or more nitro groups.
D010073	Oxamniquine	An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121)	Oxaminiquine,UK-4271,UK 4271,UK4271
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012550	Schistosoma mansoni	A species of trematode blood flukes of the family Schistosomatidae. It is common in the Nile delta. The intermediate host is the planorbid snail. This parasite causes schistosomiasis mansoni and intestinal bilharziasis.	Schistosoma mansonus,mansonus, Schistosoma
D012555	Schistosomiasis mansoni	Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.	Schistosomiasis, Intestinal,Schistosoma mansoni Infection,Infection, Schistosoma mansoni,Infections, Schistosoma mansoni,Intestinal Schistosomiases,Intestinal Schistosomiasis,Schistosoma mansoni Infections,Schistosomiases, Intestinal